Stem Cell Therapy Could Be Breakthrough Against Type 1 Diabetes
WEDNESDAY, Oct. 4, 2023 -- People with type 1 diabetes lack functional islet cells in their pancreas to produce the hormone insulin and must take daily insulin via injections or a continuous pump to compensate.
But if new research pans out, some... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 4, 2023 Category: General Medicine Source Type: news
Salvage Option to Replace Transplant in RR Hodgkin Lymphoma? Salvage Option to Replace Transplant in RR Hodgkin Lymphoma?
A chemoimmunotherapy and radiation combination without autologous stem cell transplant produced high response rates in children and young adults with low-risk relapsed/refractory Hodgkin lymphoma.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - October 3, 2023 Category: Radiology Tags: Hematology-Oncology News Source Type: news
FDA Advisers Vote Against Experimental ALS Treatment
The panel of Food and Drug Administration experts voted 17-1 that drugmaker Brainstorm's stem cell-based treatment has not been shown effective for patients with the fatal, muscle-wasting disease known as ALS. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - October 2, 2023 Category: American Health Source Type: news
Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD
Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitorfenebrutinib in multiple sclerosis (MS) will be presented10-year OCREVUS efficacy and safety data show significant benefit in slowing long-term disability progression and consistent long-term safety profile in MSAdditional OCREVUS real-world and clinical data show impact for underrepresented populations including more than 3,200 pregnant women and Black and Hispanic/Latinx patients with MSLonger-term safety data and late-breaking efficacy data from Phase III trial of ENSPRYNG (satralizumab) inneurom...
Source: Roche Media News - October 2, 2023 Category: Pharmaceuticals Source Type: news
Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD
Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitorfenebrutinib in multiple sclerosis (MS) will be presented10-year OCREVUS efficacy and safety data show significant benefit in slowing long-term disability progression and consistent long-term safety profile in MSAdditional OCREVUS real-world and clinical data show impact for underrepresented populations including more than 3,200 pregnant women and Black and Hispanic/Latinx patients with MSLonger-term safety data and late-breaking efficacy data from Phase III trial of ENSPRYNG (satralizumab) inneurom...
Source: Roche Investor Update - October 2, 2023 Category: Pharmaceuticals Source Type: news
Stem Cell Transplants Effective in MS
(MedPage Today) -- Most patients with relapsing-remitting multiple sclerosis (RRMS) treated with autologous hematopoietic stem cell transplantation (AHSCT) showed no evidence of disease activity (NEDA) for 5 to 10 years, observational data showed... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - September 30, 2023 Category: Neurology Source Type: news
FDA Panel Says No to Experimental ALS Drug
THURSDAY, Sept. 28, 2023 -- An advisory panel to the U.S. Food and Drug Administration on Wednesday voted resoundingly against recommending a stem cell-based experimental treatment for amyotrophic lateral sclerosis (ALS).
Although the FDA is not... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 28, 2023 Category: Pharmaceuticals Source Type: news
Experimental ALS Drug Will Not Be Approved
THURSDAY, Sept. 28, 2023 -- An advisory panel to the U.S. Food and Drug Administration on Wednesday voted resoundingly against recommending a stem cell-based experimental treatment for amyotrophic lateral sclerosis (ALS).
Although the FDA is not... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 28, 2023 Category: Pharmaceuticals Source Type: news
FDA Panel Says No to Experimental ALS Drug
THURSDAY, Sept. 28, 2023 – An advisory panel to the U.S. Food and Drug Administration on Wednesday voted resoundingly against recommending a stem cell-based experimental treatment for ALS.
Although the FDA isn ' t bound by the votes of its advisory... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 28, 2023 Category: General Medicine Source Type: news
FDA Panel Says No to Experimental ALS Drug, NurOwn
THURSDAY, Sept. 28, 2023– An advisory panel to the U.S. Food and Drug Administration on Wednesday voted resoundingly against recommending, NurOwn, a stem cell-based experimental treatment for ALS.
Although the FDA isn ' t bound by the votes of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 28, 2023 Category: General Medicine Source Type: news
FDA Panel Rejects Experimental Stem Cell Therapy for ALS FDA Panel Rejects Experimental Stem Cell Therapy for ALS
An FDA advisory panel resoundingly rejected NurOwn, an experimental stem cell therapy for mild to moderate ALS.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - September 28, 2023 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Source Type: news
Cell Culture Collective, Inc. Announces Partnership with Defined Bioscience, Inc. to Distribute Serum-Free Stem Cell Culture Products
Through this collaboration, Cell Culture Collective will become an authorized distributor for Defined Bioscience's optimized animal/serum-free stem cell culture products. (Source: The Scientist)
Source: The Scientist - September 27, 2023 Category: Science Tags: The Marketplace The Scientist Source Type: news
Stem Cell Treatment Halts MS for Some Patients
WEDNESDAY, Sept. 27, 2023 -- A new study is strengthening the evidence that stem cell transplants can be highly effective for some people with multiple sclerosis -- sending the disease into remission for years, and sometimes reversing... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 27, 2023 Category: General Medicine Source Type: news
FDA Review Skeptical of ALS Stem Cell Therapy FDA Review Skeptical of ALS Stem Cell Therapy
The FDA has raised concerns about the safety and efficacy of an experimental stem cell therapy for ALS scheduled for a public hearing by a federal advisory panel on Wednesday.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - September 27, 2023 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Source Type: news
aHSCT Beneficial for Most Patients With Relapsing-Remitting MS
TUESDAY, Sept. 26, 2023 -- Autologous hematopoietic stem cell transplantation (aHSCT) for treatment of relapsing-remitting multiple sclerosis (RRMS) yields freedom from disease activity for most patients, according to a study published online Sept.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 26, 2023 Category: Pharmaceuticals Source Type: news
